May. 28 at 4:54 PM
$ALXO Wall Street analysts' consensus remains unanimously "Buy," with average price targets above
$4.30 (more than double the current value). Seeing a stock stagnate can be boring, but in biotech, "no movement" equates to stability. It's a sign that no one is running away and that strong hands are simply waiting for medical advances in the coming months.🙂
